+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Engineered T Cell"

Global Photoimmunotherapy Market by Therapeutic Area, End-user, and Region: Competition Forecast and Opportunities to 2027 - Product Thumbnail Image

Global Photoimmunotherapy Market by Therapeutic Area, End-user, and Region: Competition Forecast and Opportunities to 2027

  • Report
  • October 2022
  • 118 Pages
  • Global
From
Engineered T Cells Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Engineered T Cells Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • June 2022
  • 96 Pages
  • Global
From
Engineered T Cells Market by Type (Chimeric Antigen Receptor Modified T Cells, T Cells Receptor Modified T Cells and Tumor Infiltrating Lymphocytes), Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021--2030 - Product Thumbnail Image

Engineered T Cells Market by Type (Chimeric Antigen Receptor Modified T Cells, T Cells Receptor Modified T Cells and Tumor Infiltrating Lymphocytes), Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021--2030

  • Report
  • February 2022
  • 227 Pages
  • Global
From
Second Generation Cell and Gene-Based Therapies. Biological Advances, Clinical Outcomes and Strategies for Capitalisation - Product Thumbnail Image

Second Generation Cell and Gene-Based Therapies. Biological Advances, Clinical Outcomes and Strategies for Capitalisation

  • Book
  • February 2020
Gene-Based Therapies for Pediatric Blood Diseases, An Issue of Hematology/Oncology Clinics of North America. The Clinics: Internal Medicine Volume 36-4 - Product Thumbnail Image

Gene-Based Therapies for Pediatric Blood Diseases, An Issue of Hematology/Oncology Clinics of North America. The Clinics: Internal Medicine Volume 36-4

  • Book
  • July 2022
  • North America
Loading Indicator

Engineered T Cells are a type of biotechnology that involves the genetic engineering of a patient's own T cells to create a personalized therapy for the treatment of cancer and other diseases. This technology is based on the idea of using the body's own immune system to fight disease. The engineered T cells are modified to recognize and attack cancer cells, while leaving healthy cells unharmed. This technology has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. Engineered T Cells are a rapidly growing field of biotechnology, with many companies developing new treatments and therapies. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in this field, developing innovative treatments and therapies for cancer and other diseases. Other companies such as Cellectis, Bluebird Bio, and Bellicum Pharmaceuticals are also making significant contributions to the field. Show Less Read more